Abstract: Treatment with beta-blockers appears to show inferior reduction in central versus peripheral blood pressure. We aimed to examine simultaneous changes in central and peripheral blood pressure, vascular resistance, cardiac function and arterial stiffness during beta-blockade. Haemodynamics were investigated after 3 weeks of bisoprolol treatment (5 mg/day) in a double-blind, randomized, placebo-controlled cross-over trial in never-treated 16 Caucasian males with grade I-II primary hypertension using continuous tonometric pulse wave analysis and whole-body impedance cardiography. Bisoprolol decreased radial (134/80 versus 144/89 mmHg) and aortic blood pressure (122/80 versus 130/90 mmHg) and heart rate (57 versus 68 beats/min) when compared with placebo (p < 0.05 for all). Ejection duration (336 versus 316 ms) and stroke volume (109 versus 98 ml) were increased (p < 0.01 for all), while cardiac output was not significantly changed (6.2 versus 6.6 l/min). Bisoprolol decreased pulse wave velocity (7.8 versus 8.9 m/s, p < 0.001), but after adjustment for blood pressure, the decrease was not significant (8.16 versus 8.52 m/s, p = 0.464). The treatment reduced pulse pressure amplification from central to peripheral circulation (30 versus 38%, p = 0.002). No differences were observed in systemic vascular resistance, augmentation index, aortic characteristic impedance or total arterial stiffness after bisoprolol versus placebo. Bisoprolol decreased central and peripheral blood pressure and pulse wave velocity in male individuals with grade I to grade II hypertension. The decrease in pulse wave velocity was related to the antihypertensive effect. Reduced pulse pressure amplification indicates that peripheral blood pressure was reduced more efficiently than central blood pressure.
Recent studies have reported inferiority of beta-adrenoceptor blockers (beta-blockers) compared with other classes of antihypertensive drugs in the prevention of cardiovascular events in hypertensive individuals [1, 2] , and they are no more among the first-line treatment options of primary hypertension. However, individuals with recent myocardial infarction or heart failure benefit from treatment with beta-blockers [3] [4] [5] .
All classes of antihypertensive drugs have been shown to equally lower brachial blood pressure (BP) [6] . However, the change in BP at the brachial level does not directly reflect changes in central BP because of pulse wave amplification, that is increase in the amplitude of pulse pressure as it travels from central to peripheral arteries [7] . The inferiority of betablockers in preventing cardiovascular events might be due to the lower reduction in aortic BP when compared with vasodilating antihypertensive drugs [8] . The lowering of central BP is an important target in the treatment for hypertension, because the superiority of central over peripheral BP in the prediction of future cardiovascular events has been shown [9, 10] .
Most of the large trials on the haemodynamic effects of beta-blockers have examined atenolol or metoprolol [2, 8] , and it is not clear whether the observed results represent the class effects of beta-blockers. The haemodynamic influences of beta-blockers have been largely attributed to reduction in cardiac output (CO) [11, 12] , but this variable is not commonly measured even in research settings. Systemic vascular resistance (SVR) has been measured in some studies, and the findings have shown no significant reductions in SVR after treatment with bisoprolol, atenolol [13] or metoprolol [14] .
Conflicting results regarding the effect of beta-blockers on central BP have been published: a decrease in central systolic pressure and pulse pressure [14] [15] [16] , a decrease in central systolic and diastolic but not pulse pressure [17] and a decrease in central diastolic pressure [13] have been reported. The results on the effects of non-vasodilating beta-blockers on pulse wave velocity (PWV), a marker of arterial stiffness, have also been controversial. Some studies [17] [18] [19] [20] , but not all reports [13, [21] [22] [23] , have shown significant reductions in PWV. In general, beta-blockers do not seem to have a beneficial effect on augmentation index (AIx), a variable presenting the impact of the reflected pressure wave on central systolic BP [13] [14] [15] [16] [17] 23] . However, the heterogeneous nature of the study settings, use of other antihypertensive medications, diverse gender distributions and various haemodynamic measurement protocols make the comparisons between different studies difficult.
In the present double-blind, placebo-controlled cross-over trial, we recorded radial and aortic BP, vascular resistance, cardiac function and arterial stiffness in never-treated male individuals with grade I to grade II essential hypertension to examine the haemodynamic changes induced by bisoprolol treatment.
Materials and Methods
Individuals. Sixteen non-smoking male volunteers, aged 39-55 years, with untreated, grade I to grade II essential hypertension participated in the study. In accordance with the European evidence-based clinical practice guidelines for hypertension, systolic office BP between 140-180 mmHg and diastolic BP between 90-109 mmHg were considered grade I to grade II hypertension [24] .
The individuals accepted for the study were recruited via announcements in a local newspaper (n = 14) and occupational healthcare units (n = 2). Before entering the study, all volunteers were subjected to an interview and physical examination performed by a physician. Lifestyle habits, medical history and physical status with office BP measurements (mean value of two consecutive brachial BP readings using a manual sphygmomanometer in seated position) were documented, standard 12-lead electrocardiogram was recorded, and routine laboratory tests for hypertension were taken [24] . The exclusion criteria were as follows: use of antihypertensive medication, secondary hypertension, marked obesity (BMI > 35 kg/m 2 ), current smoking, large-scale alcohol consumption (>24 restaurant doses/week), bradycardia (HR < 50 beats/min at the medical examination), known heart disease, diabetes mellitus, cerebrovascular or peripheral arterial disease and pulmonary disease. Two of the study individuals were on statin treatment for hypercholesterolaemia and two individuals on selective serotonin reuptake inhibitors for depression. Two individuals had a diagnosis of gastro-oesophageal reflux disease without regular medication, and one individual was on thyroxine substitution for hypothyroidism with a stable euthyroid state.
All individuals gave written informed consent to participate in the study. The study complied with the Declaration of Helsinki and was approved by the ethics committee of Tampere University Hospital (study code R09103M) and registered in a database (clinical trials registration NCT01742702).
Study design and research drugs. The study design was a doubleblind, randomized, placebo-controlled cross-over trial that consisted of three 3-week periods ( fig. 1 ). During the first and the third 3-week periods, bisoprolol 5 mg (Orion Corporation, Espoo, Finland) or placebo (Tampere University Hospital Pharmacy, Tampere, Finland) was administered once daily, while the second period was a wash-out period without any medication. The dose was chosen, as 5 mg of bisoprolol once daily effectively reduced ambulatory 24-hr BP versus placebo in middle-aged Finnish men [25] . Sample size calculation was based on the assumption that bisoprolol treatment will lower diastolic BP ≥ 6 mmHg with a standard deviation (S.D.) of 6 mmHg [6, 26, 27] . At least 13 individuals were needed to have statistical power of 90% (two-sided alpha = 0.05). Sixteen individuals were recruited, and every individual completed the protocol.
The study individuals were randomized into two groups determining the order of the treatment. Randomization was performed in blocks of four by the pharmacy of the Tampere University Hospital, which was not involved in the examination of the study individuals. The protocol included paired home BP measurements on 2 days during each treatment week (Microlife WatchBP Home â ; Widnau, Switzerland; gift from Darius Milkevicius, Microlife, Lithuania).
Haemodynamic measurements. Haemodynamic measurements were performed at the end of the first and the third 3-week periods (placebo and bisoprolol treatments in randomized order) in a research laboratory by trained nurses using continuous whole-body impedance cardiography with simultaneous radial pulse wave analysis [28, 29] . Prior to the measurements, the individuals were instructed to refrain from caffeine-containing products, smoking and heavy meals for at least 4 hr, and from alcohol use for at least 24 hr. Before the actual measurement, the individuals were resting supine for approximately 10 min., and the electrodes for impedance cardiography were placed on the body surface, a tonometric sensor for pulse wave analysis was fixed to the left wrist on the radial pulsation, and a brachial cuff for BP calibration was placed to the right upper arm. Haemodynamic variables were then continuously captured in a beat-to-beat fashion for 5 min. in a supine position. The good repeatability and reproducibility of the haemodynamic measurements have been previously shown [28] .
Pulse wave analysis and whole-body impedance cardiography. Radial BP and pulse wave form were recorded by the use of an automatic tonometric sensor (Colin BP-508T; Colin Medical Instruments Corp., San Antonio, Texas, USA) [28, 29] . The radial BP signal was calibrated approximately every 2.5 min. by contralateral brachial BP measurements. Aortic pressures were derived from the radial signal with the SphygmoCor pulse wave monitoring system (SphygmoCor PWMx; AtCor Medical, West Ryde, New South Wales, Australia) using a validated generalized transfer function [30] . From the aortic pulse wave form, AIx (augmented pressure/pulse pressure*100%), AIx adjusted to heart rate (HR) 75/min (AIx@75) and Buckberg subendocardial viability ratio [31, 32] were determined using the SphygmoCor software.
A whole-body impedance cardiography device (CircMon â ; JR Medical Ltd, Tallinn, Estonia) was used to determine beat-to-beat HR, stroke volume, CO and PWV [33] [34] [35] . SVR was calculated from the signal of the radial tonometric BP sensor and the CO measured by CircMon â . The stroke volume and CO values measured using CircMon â are in good agreement with values measured using threedimensional ultrasound and the thermodilution method, respectively [34, 36] . To calculate PWV, the CircMon software measures the time difference between the onset of the decrease in impedance in the wholebody impedance signal and the popliteal artery signal to determine aortic-to-popliteal PWV [33] . The recorded PWV values show very good correlation with values measured using ultrasound or the tonometric SphygmoCor method [33, 37] .
The central forward wave amplitude was determined as the difference between pressure at the waveform foot and pressure at the first systolic inflection point of the aortic pressure waveform [38] . Time Fig. 1 . Study design. Altogether 16 middle-aged men were allocated to bisoprolol or placebo for 3 weeks in a randomized, double-blind, cross-over study. Haemodynamic measurements were performed at the end of the 3-week treatment periods. domain estimates of total arterial stiffness [((pressure at inflection point À diastolic aortic pressure)*systolic time)/(stroke volume*time to inflection point)], and characteristic impedance of the aorta [(pressure at inflection point À diastolic aortic pressure)*systolic time)/ (stroke volume*2)] were calculated according to Chemla et al. [39] .
Laboratory analyses. Blood and urine samples were obtained in the morning after an approximately 12-hr fast. Plasma sodium, potassium, creatinine, glucose, triglyceride and total, high-density and low-density lipoprotein cholesterol concentrations were determined by Cobas Integra 700/800 (F. Hoffmann-Laroche Ltd, Basel; Switzerland) or Cobas6000, module c501 (Roche Diagnostics, Basel, Switzerland), and blood cell count by ADVIA 120 or 2120 (Bayer Health Care, Tarrytown, NY, USA). Urine dipstick analysis was made by an automated refractometer test (Siemens Clinitek Atlas or Advantus, Siemens Healthcare GmbH, Erlangen, Germany). As the creatinine values were within the normal range in all but one individual, estimated glomerular filtration rate (GFR) was calculated using the RULE formula [40] .
Statistical analyses. The mean value of each haemodynamic variable during the 5 min. of recording was used in the statistical analyses. Continuous variables were summarized as means and standard deviations (S.D., table and text in the Results section), and figures were depicted as medians, 25th-75th percentile and range. To study the treatment effect of bisoprolol, the variables were analysed with an analysis of variance (ANOVA) model for cross-over studies taking into account the treatment (placebo or bisoprolol), sequence period and patients nested within the sequence assuming that no carry-over effect (effect of the first treatment on the latter) exists. In adjusted univariate analyses, the confounding factors were used as covariates. The washout period for 3 weeks in between the bisoprolol and placebo treatments was considered sufficient to rule out the carry-over effect of bisoprolol on the period with placebo treatment, as the half-life of bisoprolol is approximately 10-12 hr and the full treatment effect of bisoprolol is reached within 2 weeks [41] . According to Shapiro-Wilk test, all variables except for stroke volume at the end of the placebo period were normally distributed, and even this stroke volume distribution was normal according to the Kolmogorov-Smirnov test. Importantly, the applied ANOVA model is not sensitive to moderate deviations from normality. Correlations between the variables were tested using Spearman's test. Statistical analyses were performed using Stata 8.2. (StataCorp, College Station, TX, USA) and SPSS statistics 17.0 (SPSS Inc., Chicago, IL, USA).
Results

Study population.
The demographic data, office and home BP recordings, and laboratory values are presented in table 1. All of the enrolled 16 individuals (aged 39-55 years) completed the study. None of the individuals were present smokers, while seven had a previous smoking history (time from smoking cessation 13 AE 6 years). Average self-reported alcohol consumption among the study population was five standard doses (each of 12 g alcohol) per week, and amount of physical exercise 3 AE 1 times weekly (one session ≥30 min.). Three of the individuals had left ventricular hypertrophy according to the Sokolow-Lyon criteria (SV1 + RV5/6 ≥ 35 mm). Blood cell count, sodium, potassium and fasting plasma glucose concentrations were within the normal range in all individuals, and none had haematuria or proteinuria. One individual had slightly elevated plasma creatinine value (113 lmol/l) with an estimated GFR of 83 ml/min. Total cholesterol values ranged 3.7-6.4 mmol/l, LDL cholesterol 2.1-4.5 mmol/l, HDL cholesterol 0.9-2.0 mmol/l and triglycerides 0.52-2.4 mmol/l (table 1). The use of medications was minimal (see Materials and Methods).
Mean office BP at screening was 149/99 mmHg and HR 67 beats/min. Home BP and HR during the last treatment week with bisoprolol were significantly lower (131/82 mmHg, 57 beats/min) when compared with placebo (141/92 mmHg, 69 beats/min, p < 0.001) (table 1).
Haemodynamic measurements.
The box plots representing the haemodynamic variables at the end of the treatment periods with placebo or bisoprolol are shown in figs 2-4. Both radial and aortic BP were reduced after bisoprolol treatment ( fig. 2 ): radial systolic BP was À10 AE 10 mmHg and diastolic BP À9 AE 10 mmHg lower, and aortic systolic/diastolic BP was À8 AE 10/ À9 AE 10 mmHg lower after bisoprolol treatment when compared with placebo (mean AE S.D., p < 0.007 for all BPs).
Heart rate was À11 AE 6 beats/min lower, and ejection duration 20 AE 13 ms longer after bisoprolol ( fig. 3A,B) . Stroke volume was increased after bisoprolol treatment (by BP, blood pressure; GFR, glomerular filtration rate estimated using the RULE formula [40] . *p < 0.001 versus corresponding measurement during placebo.
12 AE 11 ml, fig. 3C ), but CO did not significantly change (À0.42 AE 1.0 l/min, fig. 3D ). Bisoprolol increased subendocardial viability ratio (+25 AE 21%, fig. 3E ), while there was no significant treatment effect on SVR ( fig. 3F ).
There was no significant difference in radial pulse pressure (À1.1 AE 8.6 mmHg, p = 0.624) or aortic pulse pressure (À1.5 AE 6.2 mmHg, fig. 4A ) after bisoprolol when compared with placebo. However, radial pulse pressure over aortic pulse pressure, that is pulse pressure amplification, was decreased after bisoprolol (À8 AE 10%, fig. 4B ). Aortic AIx (2.0 AE 4.6%, fig. 4C ), AIx@75 (À2.2 AE 5.2%, p = 0.116), forward wave amplitude (À0.2 AE 5.0 mmHg, p = 0.878) and characteristic impedance of the aorta (1.8 AE 8.3 mmHg*ms/ ml, fig. 4D ) did not differ after bisoprolol versus placebo. Augmentation pressure, that is the magnitude of the reflected wave (mmHg), was numerically but not significantly higher after bisoprolol (1.31 AE 2.6 mmHg, p = 0.063). Total arterial stiffness was not significantly influenced by the treatment (À0.07 AE 0.16 mmHg/ml, fig. 4E ), while aortic-to-popliteal PWV was reduced after bisoprolol when compared with placebo (À1.1 AE 0.7 m/s, fig. 4F ). However, if the PWV values were adjusted for the prevailing mean aortic pressure in univariate analysis, the difference was no more significant (bisoprolol 8.16 versus placebo 8.52 m/s, p = 0.464). 
Discussion
The present double-blind, placebo-controlled, cross-over study examined the haemodynamic effects of the widely used beta-blocker bisoprolol in middle-aged men with grade I to grade II hypertension. The metabolic and physical profiles of the study individuals were well representative of the typical hypertensive patients [24] . The measurement protocol included recording of CO, SVR and large artery stiffness in addition to pulse wave analysis. The results demonstrated that bisoprolol treatment decreased radial BP, aortic BP and aortic-to-popliteal PWV, in the absence of significant changes in aortic characteristic impedance, total arterial stiffness, central pressure augmentation or SVR. In addition, subendocardial viability ratio was improved, while amplification of pulse pressure was decreased after bisoprolol. These findings show that bisoprolol treatment reduced central BP and PWV, even though the effect on central wave reflection was not beneficial. The fact that a corresponding reduction in mean BP after bisoprolol was observed both at home and in the laboratory increases the reliability of the results.
The adherence to the study medication can be assumed to have been good, based on the observed reduction in heart rate and increase in ejection duration, representing typical cardiac effects of beta-blockers [42] . In parallel, reduced heart rate was associated with increased stroke volume, which probably explains the absence of statistically significant reductions in CO. Although SVR was not changed, bisoprolol reduced systolic and diastolic BPs both at the radial and at aortic levels. As BP is defined as the product, not sum, of CO and SVR, the reduction in mean BP after bisoprolol can most likely be attributed to the cardiac effects of this compound. We also observed a clear increase in subendocardial viability ratio, a variable derived from pulse wave analysis that evaluates myocardial oxygen supply versus demand [31] . This variable may also serve as an index of impaired coronary flow reserve in hypertensive patients [32] .
Due to pulse pressure amplification, changes in brachial BP do not directly reflect changes in central BP [7] . We found that pulse pressure amplification was decreased after bisoprolol, indicating a more efficient lowering of radial versus aortic BP. This agrees with previous findings obtained with nonvasodilating beta-blockers [43, 44] . We did not observe significant changes in AIx or AIx@75, both of which are approximate measures of wave reflection [45] , after bisoprolol treatment. This lack of the beneficial effects on central wave reflection was probably a consequence of lower HR and prolonged ejection duration during beta-blockade ( fig. 2A,B) . Although lower BP can be expected to result in lower AIx, prolonged ejection period results in the return of the reflected pressure wave earlier during systole, the mechanism of which may augment systolic BP [8] . On the other hand, longer left ventricular ejection period may reduce the transmission speed of the systolic pressure wave in the arterial tree [46] . This mechanism would delay the return of the reflected wave. Thus, the two aforementioned changes in cardiac kinetics have opposite influences on the magnitude of the AIx during betablockade.
Large artery stiffness can be evaluated using many different techniques, the most direct one of which is the measurement of PWV. This method records the propagation of the Fig. 4 . Indices of arterial stiffness after bisoprolol and placebo. Box plots show aortic pulse pressure (A), pulse pressure amplification (B), augmentation index (C), aortic characteristic impedance (D), total arterial stiffness (E) and pulse wave velocity (F) during haemodynamic measurements at the end of the 3-week bisoprolol or placebo periods; median (bold line inside box), 25th-75th percentile (box) and range (whiskers).
peak systolic pressure wave in the arterial tree [47, 48] . The present results showed that aortic-to-popliteal PWV was reduced after the bisoprolol treatment, a finding suggestive of improved large artery stiffness. However, the 3-week treatment period is too short for significant anatomical changes to take place in large arteries. Indeed, when adjusted for the level of central BP, the observed reduction in PWV was no more significant. As the prevailing level of BP is one of the most important determinants of PWV [49] , the reduction in BP after bisoprolol treatment can probably largely explain the observed beneficial influence on PWV. We also evaluated arterial stiffness by calculating total arterial stiffness and characteristic impedance of the aorta, the latter which describes the impedance of the aorta in the absence of wave reflections [39] . As bisoprolol treatment did not significantly influence either of these variables, this further supports the view that the above reduction in PWV was largely attributed to the lowering of BP. Additionally, both higher HR and shorter ejection duration have been reported to show an increasing influence on PWV [45] . Changes in cardiac kinetics during beta-blockade may thus partially explain the above beneficial findings on PWV.
Beta-blockers are a heterogeneous group of drugs with divergent adrenoceptor selectivity and pharmacokinetic and pharmacodynamic properties. The large trials on the long-term haemodynamics of beta-blockers examined the influences of atenolol or metoprolol [2, 8] . Although widely used in clinical practice, the more beta-1-selective bisoprolol has been less extensively studied. As beta-2 adrenoceptors are known to mediate vasodilation [50] , the higher beta-1 selectivity of bisoprolol could result in lesser blockade of the beta-2 adrenoceptors and lower influence on SVR when compared to compounds with less beta-1 selectivity. There is only scarce information about the influence of bisoprolol on SVR, but a study with 20 individuals showed no effect on vascular resistance [51] . This view agrees with the results of the present study, and also with other investigations on non-vasodilating beta-blockers [13, 14] . However, the newer cardioselective beta-blocker nebivolol may also have vasodilatory and antiinflammatory effects [52] , carvedilol exhibits alpha-1-blocking properties, while pindolol has an intrinsic sympathomimetic activity [50] . Hence, the results of the present study should not be considered as class effects of all beta-blockers.
Our study has some limitations. The study population was small and consisted of men only. Still, several haemodynamic changes induced by bisoprolol were observed even in this relatively small population. Significant gender differences have been previously reported, for example, in central wave reflection [53] and upright haemodynamics [54] , and the results may not be applicable to women. The haemodynamic recordings of the present study were non-invasive and required mathematical computations and estimations. However, the methods have been previously validated against invasive measurements with good results [30, 34] . Furthermore, invasive measurements of haemodynamics would not be justified in individuals with grade I-II hypertension as the only indication.
The present aortic-to-popliteal PWV values were recorded using the bioimpedance signal and not the carotid-femoral tonometry that is considered the gold standard method [47] . However, we have previously shown that the PWV values recorded using whole-body bioimpedance correlate very well with values measured using ultrasound or the tonometric SphygmoCor method [33, 37] . It is very unlikely that the medications used by the study individuals (two on statins, two on selective serotonin reuptake inhibitors, one on thyroxine) or the mild gastro-oesophageal reflux problems of two individuals not needing regular medications, would have influenced the results due to the randomized, double-blind, cross-over study design. In addition, thyroxine substitution has been reported not to influence arterial stiffness and central haemodynamics, providing that the individuals are in a stable euthyroid state [55] .
In conclusion, treatment with bisoprolol decreased central and peripheral BP and improved subendocardial viability index in never-treated middle-aged male individuals with grade I-II hypertension. The lowering of BP was probably explained by the cardiac effects of the compound, as no changes in SVR were observed. Reduced pulse pressure amplification after bisoprolol indicates that peripheral blood pressure was reduced more effectively than central blood pressure. Bisoprolol treatment also improved PWV, and this effect appeared to be secondary to the lowering of BP.
